Problems With the Interpretation of Pharmacoeconomic Analyses: A Review of Submissions to the Australian Pharmaceutical Benefits Scheme

Article Abstract:

Many pharmacoeconomic analyses are poorly done and should not be used as the basis of drug selection policies. These reports contain a cost-benefit analysis of the drug and are used by governments and managed care companies to make drug reimbursement decisions. Of 326 reports submitted by the pharmaceutical industry to the Australian Department of Health and Aged Care (DHAC) under the Australian Pharmaceutical Benefits Scheme, 218 had serious methodological problems and 31 had more than one problem. Many of these problems were avoidable.

---

Pharmacoeconomic Analyses: Making Them Transparent, Making Them Credible

Article Abstract:

Researchers and journal editors must do their part to ensure the quality of pharmacoeconomic analyses. These are reports analyzing the clinical trials of a drug to see if the drug is cost-effective. Many governments and managed care companies require these analyses before adding the drug to a formulary. An Australian study published in 2000 found that 67% of the pharmacoeconomic analyses studied were not well-done. Journal editors can insist that researchers follow published guidelines for writing such analyses.

Editorial, Research

---

Drug prices and value for money: The Australian pharmaceutical benefits scheme

Article Abstract:

The work of the National Institute for Health and Clinical Excellence (NICE), the main health technology assessment agency in the UK and the Pharmaceutical Benefits Advisory Committee (PBAC) is described. Both the organizations show that decisions about funding new drugs can be based on formal measures of cost-effectiveness.

United Kingdom, Australia, Drugs & Pharmaceuticals, Pharmaceutical and Medicine Manufacturing, Pharmaceutical Preparation Manufacturing, Commodity & service prices, Pharmaceutical preparations, Drugs, Metabolic Agents NEC, Metabolic Agents, Prices and rates, Company pricing policy

Similar abstracts:

• Abstracts: The moral foundation of medical leadership: the professional virtues of the physician as fiduciary of the patient
• Abstracts: Costs, outcomes, and patient satisfaction by provider type for patients with rheumatic and musculoskeletal conditions: a critical review of the literature and proposed methodological standards
• Abstracts: Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease
• Abstracts: Freedom to practise: the doctor-nurse relationship. Freedom to practise: changes in daily practice. Freedom to practise changing ward culture
• Abstracts: An overview of managing anaphylaxis in the community. Hypothermia management. Anaphylaxis: emergency management

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.